Grünenthal Group

BehaVR and Fern Health Merge To Form RealizedCare, Launch Digital Care Management Platform to Unlock the Value of Digital Therapeutics

Share

The merger will accelerate a new digitally-powered care management solution for chronic pain and beyond; Pharmaceutical company Grünenthal becomes the largest investor in the combined enterprise

NASHVILLE, Tenn., Aachen, Germany, NOVEMBER 16, 2023 – BehaVR, a pioneering force in digital therapeutics (DTx) experiences, and Fern Health, a virtual chronic pain management program, today announced the signing of an agreement to merge their businesses and create a new digital care management solution for chronic pain. The new offering will be branded as RealizedCare, and strives to meet the increased demand for evidence-based, more scalable, impactful and economically viable solutions for a range of mental and behavioral health burdens, beginning with chronic pain.

RealizedCare introduces an advanced care management platform powered by DTx technology. The platform’s approach, which combines DTx with traditional wraparound services, will unlock value-based chronic pain management at scale. Grünenthal, a global research-based pharmaceutical company and parent company of Fern Health, has partnered with RealizedCare as a strategic investor, delivering on its shared vision of a world free of pain.

Chronic pain impacts an estimated 52 million adults in the United States and drives an estimated $261 billion to $300 billion in direct healthcare costs per year. Due to the highly individual and complex nature of persistent pain, health plans and providers have long struggled to adequately support those who experience it and manage the associated costs. RealizedCare’s disruptive offering represents a pivotal moment in the evolution of care delivery.

“We’ve spent the last five years building, perfecting and validating evidence-based, immersive, digital therapeutics designed to address fear and pain,” said Aaron Gani, founder and CEO of BehaVR and CEO of RealizedCare.“Through this new offering, we will unlock the power of those interventions to scale personalized care to individuals impacted by chronic pain in a way that prioritizes outcomes, and offers the integrated support needed to manage these symptoms effectively.”

RealizedCare will work with health plans, employers and value-based providers to identify, assess and engage members with chronic pain via a fully managed solution. With RealizedCare, members and patients are guided through a personalized care journey, receive digital interventions, are connected to a community with lived experience of chronic pain and can be referred directly to clinicians when necessary.

“Chronic pain is on the rise globally and the demand for holistic, multi-modal care via digital solutions is growing. By positioning Fern Health at this nexus, we have developed truly innovative solutions for those who suffer from chronic pain and partnered with leading health services in the US. Through this merger, we will be able to extend the reach and impact of multi-modal digital health solutions to more people living with chronic pain,” said Gabriel Baertschi, CEO, Grünenthal.

Fern Health’s chronic pain programs were initially developed in collaboration with pain management clinicians at Massachusetts General Hospital. Fern Health has also partnered with major US healthcare services like the MetroHealth System and WebMD Health Services to bring its innovative virtual offering delivering education, activities, and tools to help people address the physical, emotional, and social causes of pain, to individuals and employers. The combination of Fern Health's innovative virtual offering with BehaVR's expertise in building immersive, evidence-based DTx will enhance engagement and impact across RealizedCare's suite of clinically validated therapeutics. This suite includes treatments across the spectrum of mental and behavioral conditions, including treatments for serious mental illness.

In multiple randomized controlled trials, including real world outcomes from over 23,000 encounters, patients who previously experienced BehaVR’s PNE (Pain Neuroscience Education) VR program had 2 ½ times greater likelihood of a clinically significant reduction in disability, as well as 20 percent improvements in pain catastrophizing.

As part of the new offering, members will be assigned a pain coach and receive a personalized care plan, inclusive of pain neuroscience education, mindfulness practices, calming experiences, and immersive, gamified, graded exercise and movement. Members will also have access to PatientsLikeMe's supportive community of over 160,000 people living with chronic pain who will provide peer and community support from those that understand the complexities and challenges of living with chronic pain. PatientsLikeMe is a trusted digital health community that supports health consumer acquisition, engagement and activation, and is the first collaborator to support the member engagement aspect of this new offering.

“We are thrilled to join RealizedCare and to enable this new offering, which supercharges the scalability and economic viability of traditional care management programs,” said Brad Lawson, CEO, Fern Health. “This is a completely different care experience for chronic pain patients that should mean better managed pain, fewer analgesic injections, fewer trips to the ER, fewer unnecessary surgeries, and ultimately, an improved quality of life.”

Keywords

Contacts

Fabia Kehren
Head of External Communication Grünenthal
E-Mail: Fabia.Kehren@grunenthal.com

About RealizedCare

RealizedCare is a leader in building evidence-based, immersive, digital therapeutics designed to create a more resilient world, liberated from fear and pain. Its suite of clinically validated therapeutics offer access to treatments on a spectrum across mental wellness and mental and behavioral conditions, including validated treatments for serious mental illness. RealizedCare is the first immersive digital therapeutics company to deliver these treatments on an integrated platform that simplifies the patient experience, enables clinician oversight, and generates patient-specific care plans and measurable outcomes. Combining a team of accomplished clinicians and researchers with proven healthcare veterans and technology innovators, RealizedCare is dedicated to improving access to better mental health through immersive technology.

More information: https://realizedcare.com

About Grünenthal

Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain.

Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the US. Our products are available in more than 100 countries. In 2022, Grünenthal employed around 4,400 people and achieved sales of € 1.7 bn.

More information: www.grunenthal.com

About Fern Health

Available through employers and health plans, Fern Health's virtual pain platform addresses the underlying causes of persistent pain, not just the symptoms. Guided programs deliver exercise therapy, interventions for sleep, nutrition, daily movement, and emotional health. Every member is supported through pain-focused 1:1 clinical coaching and pain neuroscience education to improve function, reduce pain, and avoid unnecessary healthcare costs. Fern Health is majority owned by German life science company Grünenthal International, with other minority investors. More information: www.fernhealth.com

Subscribe to releases from Grünenthal Group

Subscribe to all the latest releases from Grünenthal Group by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Grünenthal Group

Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia2.6.2025 11:49:26 EEST | Press release

Grünenthal announces that it agreed to acquire the commercial rights to Cialis® from Eli Lilly and Company in Mexico, Brazil and Colombia, further strengthening Grünenthal's footprint in Latin America. As part of the acquisition, Grünenthal will transfer the manufacturing of Cialis® to its production site in Chile. Since 2017, Grünenthal has invested more than €2 billion in successful M&A transactions, significantly strengthening its profitability.

Maren Thurow starts as new Head Global Communications at Grünenthal20.5.2025 12:12:34 EEST | Press release

Aachen, Germany, 20th May 2025 - Maren Thurow has today assumed the role of Vice President and Head Global Communications at Grünenthal. She succeeds Florian Dieckmann, who has played a key role in evolving the company’s Communications department since 2021. In her new position, Maren will oversee Grünenthal’s communications operations across all markets and lead the team based at the company’s headquarters in Aachen. She will report directly to CEO Gabriel Baertschi. This appointment comes at a pivotal moment in Grünenthal’s transformation, following the company’s outstanding financial performance in 2024. Since 2017, Grünenthal’s profitability, measured by adjusted EBITDA, has more than tripled, driven by strategic acquisitions and partnerships such as the acquisition of the US company Valinor Pharma and the product Movantik™ in July 2024. Additionally, Grünenthal continues to advance its key R&D programs, including progressing the Glucocorticoid Receptor Modulator (GRM) and Nocicept

Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal25.2.2025 08:41:18 EET | Press release

Aachen, Germany & Toronto, Canada, 24 February 2025 – Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, non-opioid pain patch indicated for the management of neuropathic pain.

Grünenthal appoints Prof. Dr. Uli Brödl as Chief Scientific Officer9.1.2025 11:54:14 EET | Press release

Aachen, Germany, 09 January 2025 – Grünenthal announced today that Prof. Dr. Uli Brödl will assume the role of Chief Scientific Officer (CSO) and Member of the Corporate Executive Board, effective 01 February 2025. Uli Brödl has more than 15 years of industry experience. He joins Grünenthal from Boehringer Ingelheim, where he served as Corporate Senior Vice President, Head of Global Clinical Development & Operations, and member of Boehringer Ingelheim's Venture Fund Investment Committee. In his most recent role, he oversaw end-to-end clinical development and operations activities across therapeutic areas and worked at the interface of R&D, Commercial, and Market Access functions. He has a proven track record of bringing innovative medicines to patients, including Empagliflozin, an oral anti-diabetic medicine. Earlier in his career, Uli Brödl led Boehringer Ingelheim's Canadian medical organisation and gained extensive market experience. In parallel, he founded and co-chaired the BI Can

Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain7.11.2024 12:44:57 EET | Press release

The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures per year in the U.S.[2] QUTENZA® is a topical system, non-systemic, non-opioid pain treatment that is currently approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Topline results are expected in Q4 2025 and Averitas Pharma aims to submit a supplemental new drug application (sNDA) for a US label extension in 2026, subject to positive data.

World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye